Should Psychedelic Facilitators Have Personal Experience? What Experts Are Saying

As states like Oregon and Colorado move forward with regulated psilocybin services, an important question has come into focus: Should facilitators have personal experience with psychedelics themselves? 

A recent qualitative study, Personal Psychedelic Experience as a Training Qualification for Facilitators, explored this exact issue. The research included insights from experts with extensive experience supporting psilocybin sessions in clinical trials, ceremonial settings, and community contexts. Among the authors was Jason Luoma, PhD, from Portland Psychotherapy, as part of a broader research team. 

Their findings offer a thoughtful look at a debate that sits at the intersection of ethics, safety, and professional training. 

Why Facilitator Training Standards Are Up for Debate 

In clinical trials of psychedelic-assisted therapy, facilitators are typically licensed professionals with advanced training. In contrast, emerging state-regulated models, such as Oregon’s, require a high school diploma and completion of a state-approved training program. Notably, these regulations are silent on whether facilitators should have had their own psychedelic experiences. 

This leaves a gap. Is firsthand experience a helpful qualification, or could it introduce bias? And more importantly, does it affect the safety and outcomes of people seeking services? 

What the Experts Said 

The study used an e-Delphi method to gather input from 36 experts with an average of over 15 years of experience facilitating psilocybin sessions. During in-depth interviews, more than half spontaneously raised the topic of personal psychedelic experience. Of those who commented, the vast majority believed it was important. 

Some described firsthand experience as “essential” or “incredibly important.” A common theme was that facilitators who have navigated altered states themselves may better understand the complexity, intensity, and unpredictability of psychedelic experiences. 

Psychedelic sessions can involve profound emotional shifts, resurfacing trauma, or challenging psychological material. Experts suggested that having lived through similar terrain might help facilitators remain grounded and less reactive when supporting people during difficult moments. 

Others emphasized depth over mere exposure. It was not just about having tried psilocybin once. It was about having enough experience to understand the “arc” of the medicine and how experiences unfold over time. 

Still, not everyone agreed. One participant questioned whether requiring personal experience would be comparable to expecting psychotherapists to have lived through the exact struggles their clients face. This minority perspective highlights the ethical complexity of making such experience a requirement. 

Possible Benefits of Personal Experience 

The experts’ comments pointed toward several possible mechanisms through which personal experience might indirectly improve care: 

1. Enhanced empathy and rapport. 

In many areas of mental health care, strong therapeutic alliance predicts better outcomes. Lived experience can sometimes strengthen trust and understanding. A facilitator who understands altered states from the inside may be more attuned to subtle cues and less likely to pathologize what is unfolding. 

2. Greater comfort with non-ordinary states. 

Psychedelic experiences can be unusual and emotionally intense. Facilitators without experiential knowledge might feel anxious or overly analytical in response. Experts suggested that personal experience could help facilitators stay steady and avoid unnecessary diagnostic framing during peak moments. 

3. Facilitator well-being and self-work. 

Several experts implied that facilitators should “work on themselves” through the same processes they guide others through. Personal growth, resilience, and self-awareness may enhance a facilitator’s capacity to offer grounded support. That said, personal growth can occur through many avenues, including traditional psychotherapy. 

Important Ethical Considerations 

Despite strong opinions from most participants, the study does not recommend mandating personal psychedelic use. 

Psychedelic experiences carry risks, including the potential for prolonged psychological distress in some cases. Requiring facilitators to use psychedelics could be unethical, particularly for those with medical or mental health contraindications. It also raises concerns about autonomy and professional boundaries. 

The researchers emphasize that we currently lack empirical evidence linking facilitator personal experience to better client outcomes or improved safety. The strong opinions captured in this study generate hypotheses, but they do not settle the debate. 

A Research Opportunity 

As legal psychedelic services expand, we now have a real-world opportunity to study this question directly. Do people experience fewer adverse events when supported by facilitators with extensive personal experience? Does therapeutic alliance differ? Are outcomes better? 

Answering these questions could inform training standards and help regulators balance safety, ethics, and professional competency. 

Moving Forward Thoughtfully 

The takeaway from this study is not a simple yes or no. Instead, it highlights the nuance. Most seasoned facilitators believe personal psychedelic experience matters. At the same time, mandating it without solid evidence could create new ethical concerns. 

As psychedelic services evolve, careful research, transparency, and open dialogue will be essential. The goal remains the same: ensuring that people seeking these services receive safe, compassionate, and high-quality care. 

You can read the full peer-reviewed article here. 

For facilitators and program designers: Portland Psychotherapy offers training and consultation for clinicians and facilitators working in psychedelic-assisted contexts. See our training resources for more. 

This article is for educational purposes and does not constitute medical advice or a recommendation to use psychedelic substances. Psychedelic-assisted therapy is currently available primarily through approved clinical trials and regulated programs such as Oregon's psilocybin services.